EUVIMEDEUVIMED entdecken
Open Access

Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation

Anisha Gupta, Christina Barone, Elias Quijano, Alexandra S Piotrowski-Daspit, J Dinithi Perera, Adele Riccardi, Haya Jamali, Audrey Turchick, Weixi Zao, W Mark Saltzman, Peter M Glazer, Marie E Egan

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2024.07.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Anisha Gupta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Gene Editing, Peptide Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein for which there is no cure. One approach to cure CF is to correct the underlying mutations in the CFTR gene. We have used triplex-forming peptide nucleic acids (PNAs) loaded into biodegradable nanoparticles (NPs) in combination with donor DNAs as reagents for correcting mutations associated with genetic diseases including CF. Previously, we demonstrated that PNAs induce recombination between a donor DNA and the CFTR gene, correcting the F508del CFTR mutation in human cystic fibrosis bronchial epithelial cells (CFBE cells) and in a CF murine model leading to improved CFTR function with low off-target effects, however the level of correction was still below the threshold for therapeutic cure. METHODS: Here, we report the use of next generation, chemically modified gamma PNAs (γPNAs) containing a diethylene glycol substitution at the gamma position for enhanced DNA binding. These modified γPNAs yield enhanced gene correction of F508del mutation in human bronchial epithelial cells (CFBE cells) and in primary nasal epithelial cells from CF mice (NECF cells). RESULTS: Treatment of CFBE cells and NECF cells grown at air-liquid interface (ALI) by NPs containing γtcPNAs and donor DNA resulted in increased CFTR function measured by short circuit current and improved gene editing (up to 32 %) on analysis of genomic DNA. CONCLUSIONS: These findings provide the basis for further development of PNA and NP technology for editing of the CFTR gene.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisGene EditingPeptide Nucleic AcidsGenetic TherapyHumansAnimalsMiceMutationEpithelial Cells

Stichwörter der Autor:innen

Cystic fibrosisGene editingPeptide nucleic acidsPolymeric nanoparticles

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorPeptide Nucleic AcidsCFTR protein, human

Autor:innen und Institutionen

  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
  • Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520, USA.
  • Department of Genetics, Yale School of Medicine, New Haven, CT 06520, USA.
  • Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
  • Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA; Department of Cellular and Molecular Physiology Yale School of Medicine, New Haven, CT 06520, USA.
  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA; Department of Genetics, Yale School of Medicine, New Haven, CT 06520, USA.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • Cystic Fibrosis Foundation

Zitieren

APA

Gupta, A., Barone, C., Quijano, E., Piotrowski-Daspit, A. S., Perera, J. D., Riccardi, A., Jamali, H., Turchick, A., Zao, W., Saltzman, W. M., Glazer, P. M., & Egan, M. E. (2025). Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.07.009

Vancouver

Gupta A, Barone C, Quijano E, Piotrowski-Daspit AS, Perera JD, Riccardi A, et al. Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.07.009

BibTeX
@article{Gupta2025,
  author = {Gupta, Anisha and Barone, Christina and Quijano, Elias and Piotrowski-Daspit, Alexandra S and Perera, J Dinithi and Riccardi, Adele and Jamali, Haya and Turchick, Audrey and Zao, Weixi and Saltzman, W Mark and Glazer, Peter M and Egan, Marie E},
  title = {Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2024.07.009}
}
Kostenlos starten →